Table 3 Estimation of malaria attack ( Pv , Pf , all species) during the prophylactic phase (6 month) of Study 033

Post deployment P. vivax relapse rate (%) amongst Study 033 subjects

1.23

Pv relapses (8/651) from CMR not original Study 033 FCSR (Equation 1)

Anti-relapse effectiveness (%) of primaquine

69.5

Estimated from John et al. 2012

Anti-relapse efficacy (%) of tafenoquine

86.3

Estimated from Walsh et al. 2004b

Anti-relapse efficacy of combined Study 033 post-exposure prophylaxis regimens

82.1

Estimated (Equation 5)

Pv attack rate (%) during prophylactic phase of Study 033

6.88

Estimated (Equation 7)

Ratio of Pf cases to Pv cases in 1999/2000 ADF deployment (InterFET)

0.146

Observed from 1999/2000 ADF deployment (Equation 4)

Pf attack rate (%) during prophylactic phase of Study 033

1.00

Estimated (Equation 8)

All malaria attack rate (%) during prophylactic phase of Study 033

7.88

Estimated (Equation 6)